Pacira Pharmaceuticals Inc (PCRX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 70.98% | 68.21% | 74.10% | 72.69% | 74.65% |
| Operating profit margin | 13.78% | 9.57% | 16.61% | 10.79% | 2.49% |
| Pretax margin | 9.70% | 2.12% | 10.42% | 4.68% | -2.55% |
| Net profit margin | 6.59% | 2.54% | 7.75% | 33.87% | -2.62% |
Pacira BioSciences Inc's profitability has shown fluctuations over the past five years. The gross profit margin has ranged from 70.11% to 74.10%, indicating a generally healthy level of profitability derived from sales after accounting for the cost of goods sold.
The operating profit margin has varied from 8.48% to 24.53%, with the most significant increase observed in 2021. This metric reflects the company's ability to generate profits from its core operations, but the fluctuations suggest some volatility in operational efficiency.
The pretax margin has ranged from -2.55% to 10.42%, with a significant improvement in 2021. This metric shows the company's ability to control operating expenses and generate profits before accounting for taxes.
The net profit margin has shown the most significant fluctuations, ranging from -2.62% to 33.87%, with a sharp decline in 2019 followed by a significant recovery in 2021. The high net profit margin in 2021 indicates efficient cost management and improved profitability for shareholders after all expenses, including taxes, have been deducted.
Overall, Pacira BioSciences Inc has demonstrated varying levels of profitability over the past five years, with improvements in certain years suggesting efforts to enhance operational efficiency and overall profitability. Continued monitoring of these profitability ratios will be essential to assess the company's long-term financial performance.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.57% | 3.57% | 4.33% | 3.64% | 1.26% |
| Return on assets (ROA) | 2.66% | 0.95% | 2.02% | 11.42% | -1.33% |
| Return on total capital | 5.93% | 3.72% | 6.27% | 4.91% | 1.95% |
| Return on equity (ROE) | 4.82% | 2.05% | 5.75% | 23.48% | -3.10% |
Pacira BioSciences Inc's profitability ratios show fluctuations over the past five years.
Operating Return on Assets (Operating ROA):
- The company's operating ROA has shown a mixed performance ranging from 4.04% to 6.40% over the period.
- The highest operating ROA was recorded in 2021 at 6.40%, indicating that the company generated $0.064 in operating income for every dollar of assets invested.
Return on Assets (ROA):
- The ROA has also varied significantly, with a high of 11.42% in 2020 and a low of -1.33% in 2019.
- In 2020, the ROA was notably high at 11.42%, suggesting strong profitability from the company's total assets.
Return on Total Capital:
- The return on total capital has been relatively stable, fluctuating between 4.76% and 7.46%.
- The company generated returns ranging from 4.76% to 7.46% on its total invested capital during the period.
Return on Equity (ROE):
- The ROE has shown significant variability, with the highest level at 23.48% in 2019 and the lowest at -3.10% in the same year.
- The company had a strong ROE in 2019 at 23.48%, indicating efficient use of equity to generate profits, while experiencing a negative ROE in the same year.
Overall, Pacira BioSciences Inc has displayed mixed profitability performance over the past five years, with some years showing strong returns on assets, total capital, and equity, while others showing lower or negative returns. Investors and stakeholders would need to analyze the company's financial performance in conjunction with other factors to assess its long-term profitability and sustainability.